Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SCIDNET

Financiado

Cerrado

DevelopIng Genetic medicines for Severe Combined Immunodeficiency SCID

Severe combined immunodeficiency (SCID) is a devastating rare disorder of immune system development. Affected infants are born without functional immune systems and die within the first year of life unless effective treatment is g... ver más

31/12/2019

UNIVERSITY COLLEGE...

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 12 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-12-31

PHC-14-2015: New therapies for rare diseases

I+D

Cerrada hace 10 años

0% 93% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

UNIVERSITY COLLEGE LONDON

1.55M€ | Lider

EIT MANUFACTURING ASBL

800.00K€ | Participante

THE RIVERS TRUST

25.00K€ | Participante

Leiden University Medical Ce...

799.88K€ | Participante

Proyectos interesantes

RECOMB

Medical Technol...

Biotechnology

6M€ Cerrado

CELL-PID

Medical Technol...

Biotechnology

16M€ Cerrado

REGENERATIVETHERAPY

Medical Technol...

Data Science

2M€ Cerrado

CRISS

Medical Technol...

Genetic Enginee...

1M€ Cerrado

SAF2017-86749-R

Medical Technol...

Genetic Enginee...

143K€ Cerrado

WASHSCGENETHERAPY

Medical Technol...

Data Science

309K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 48 meses Fecha Inicio: 2015-12-02
Fecha Fin: 2019-12-31

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Severe combined immunodeficiency (SCID) is a devastating rare disorder of immune system development. Affected infants are born without functional immune systems and die within the first year of life unless effective treatment is given. Treatment options are limited to allogeneic haematopoietic stem cell transplantation and autologous stem cell gene therapy. Over the last 15 years, gene therapy for two forms of SCID (SCID-X1 and ADA SCID) has shown significant safety and efficacy in correcting the immunodeficiency and allowing children to live normal lives. Proof of concept of gene therapy for 3 other SCID forms has also been shown by members of the proposed SCIDNET consortium and is ready for translation into clinical trials. We are therefore in a position whereby, over the next 4 years, we can offer gene therapy as a curative option for over 80% of all forms of SCID in Europe. Importantly for 1 of these conditions (ADA SCID) we will undertake clinical trials that will lead to marketing authorisation of the gene therapy product as a licensed medicine. In addition, we will investigate the future technologies that will improve the safety and efficacy of gene therapy for SCID. Our proposal addresses an unmet clinical need in SCID, which is classified as a rare disease according to EU criteria (EC regulation No. 141/2000). The proposal also addresses the need to develop an innovative treatment such as gene therapy from early clinical trials though to a licensed medicinal product through involvement with regulatory agencies and is in keeping with the ambitions of the IRDiRC. The lead ADA SCID programme has Orphan Drug Designation and clinical trial design is assisted by engagement with the European medicines Agency. The ADA SCID trial will act as a paradigm for the development of the technologies and processes that will allow gene therapy for not only SCID, but also other bone marrow disorders, to become authorised genetic medicines in the future.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores